开源自动胰岛素输送系统在1型糖尿病中的应用
这项多中心、开放标签、随机对照试验纳入97例1型糖尿病患者(48例儿童、49例成人),1:1分配至开源AID系统(AndroidAPS 2.8改良版+OpenAPS 0.7.0算法+预生产DANA-i胰岛素泵+Dexcom G6 CGM)或传感器增强胰岛素泵(对照组)。主要终点为第155至168天(试验最后2周)目标血糖范围70-180 mg/dL内时间百分比。24周时,AID组从61.2±12.3%增至71.2±12.1%,对照组从57.7±14.3%降至54.5±16.0%(调整后差异14个百分点;95%CI 9.2-18.8;P<0.001),年龄无治疗效应(P=0.56)。AID组每日目标范围内时间多3小时21分钟,两组均无严重低血糖或糖尿病酮症酸中毒发生,AID组2例因连接问题退出。
要点
- 在1型糖尿病儿童(7-15岁)和成人(16-70岁)中,开源AID系统24周时目标血糖范围内时间百分比较传感器增强胰岛素泵显著提高(调整后差异14个百分点;95%CI 9.2-18.8;P<0.001)。
- AID组目标范围内时间从61.2±12.3%增至71.2±12.1%,对照组从57.7±14.3%降至54.5±16.0%;年龄无治疗效应(P=0.56)。
- AID组每日目标范围内时间较对照组多3小时21分钟。
- 两组均未发生严重低血糖或糖尿病酮症酸中毒;AID组2例因连接问题退出试验。
适用人群与场景
- 1型糖尿病儿童(定义为7至15岁)和成人(定义为16至70岁),急诊/ICU场景未特别限定。
诊断标准与关键阈值
- 主要终点:第155至168天(试验最后2周)目标血糖范围70至180 mg/dL(3.9至10.0 mmol/L)内时间百分比。
处置流程与药物剂量
- AID系统为AndroidAPS 2.8改良版(含标准OpenAPS 0.7.0算法)联合预生产DANA-i胰岛素泵和Dexcom G6 CGM,以Android智能手机应用程序作为用户界面。
- 对照组使用传感器增强胰岛素泵。
研究设计与关键结果
- 多中心、开放标签、随机对照试验,97例患者(48例儿童、49例成人)随机分组(44例开源AID、53例对照组)。
- 24周时,AID组目标范围内时间从61.2±12.3%增至71.2±12.1%,对照组从57.7±14.3%降至54.5±16.0%(调整后差异14个百分点;95%CI 9.2-18.8;P<0.001),年龄无治疗效应(P=0.56)。
- AID组每日目标范围内时间较对照组多3小时21分钟。
- 两组均无严重低血糖或糖尿病酮症酸中毒发生;AID组2例因连接问题退出试验。
证据类型、等级与局限
- 多中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在1型糖尿病儿童和成人中,使用开源AID系统较传感器增强胰岛素泵可显著提高24周时目标血糖范围内时间百分比(作者结论)。
- 使用开源AID系统需注意连接问题,本试验中AID组有2例因此退出。
指南或共识出处
- 新西兰健康研究委员会资助;澳大利亚新西兰临床试验注册号ACTRN12620000034932。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Open-source automated insulin delivery (AID) systems are used by many patients with type 1 diabetes. Data are needed on the efficacy and safety of an open-source AID system.
METHODS: In this multicenter, open-label, randomized, controlled trial, we assigned patients with type 1 diabetes in a 1:1 ratio to use an open-source AID system or a sensor-augmented insulin pump (control). The patients included both children (defined as 7 to 15 years of age) and adults (defined as 16 to 70 years of age). The AID system was a modified version of AndroidAPS 2.8 (with a standard OpenAPS 0.7.0 algorithm) paired with a preproduction DANA-i insulin pump and Dexcom G6 CGM, which has an Android smartphone application as the user interface. The primary outcome was the percentage of time in the target glucose range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter) between days 155 and 168 (the final 2 weeks of the trial).
RESULTS: A total of 97 patients (48 children and 49 adults) underwent randomization (44 to open-source AID and 53 to the control group). At 24 weeks, the mean (±SD) time in the target range increased from 61.2±12.3% to 71.2±12.1% in the AID group and decreased from 57.7±14.3% to 54.5±16.0% in the control group (adjusted difference, 14 percentage points; 95% confidence interval, 9.2 to 18.8; P<0.001), with no treatment effect according to age (P = 0.56). Patients in the AID group spent 3 hours 21 minutes more in the target range per day than those in the control group. No severe hypoglycemia or diabetic ketoacidosis occurred in either group. Two patients in the AID group withdrew from the trial owing to connectivity issues.
CONCLUSIONS: In children and adults with type 1 diabetes, the use of an open-source AID system resulted in a significantly higher percentage of time in the target glucose range than the use of a sensor-augmented insulin pump at 24 weeks. (Supported by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12620000034932.).
参考来源
- Burnside MJ, Lewis DM, Crocket HR, et al. Open-Source Automated Insulin Delivery in Type 1 Diabetes. N Engl J Med. 2022. PMID: 36069869. doi:10.1056/NEJMoa2203913
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。